Duality Biotherapeutics, Inc. held its annual general meeting on 26 June 2026, with shareholders approving every item on the agenda by poll.

Key outcomes:

• Financial Statements Adopted – The audited consolidated results for the year ended 31 December 2025 were accepted, drawing 99.99% of votes cast (49.21 million in favour; 0.00 million against).

• Board Composition Confirmed – Shareholders re-elected four directors: Executive Director Dr Hua Haiqing, Non-executive Director Mr Cai Zhiyang, and Independent Non-executive Directors Mr Xie Dong and Ms Chuai Shuyin. Support ranged from 94.81% to 99.68% of votes cast. – The Board was authorised to determine directors’ remuneration, backed by 99.97% approval (49.20 million votes).

• Auditor Re-appointment – PricewaterhouseCoopers retained as external auditor with 94.37% support (46.44 million votes).

• Capital Management Mandates – Share repurchase mandate: Directors may buy back up to 10% of issued shares (excluding treasury shares); approved by 99.99% of votes. – Issuance mandate: Directors may allot, issue or transfer up to 20% of issued shares (excluding treasury shares); approved by 93.37% of votes. – Extension mandate: The issuance limit will be enlarged by the amount of shares repurchased; approved by 93.47% of votes.

Voting base and administration:

• Shares entitled to vote: 90.58 million, excluding 0.33 million treasury shares without voting rights. • Computershare Hong Kong Investor Services Limited acted as scrutineer. • All directors participated in the meeting, either in person or electronically.

With all ordinary resolutions passed, Duality Biotherapeutics’ board retains full authority to progress its strategic and capital-management initiatives in the year ahead.